AI Article Synopsis
- This review highlights the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) as a potential new treatment for advanced prostate cancer, especially for those with metastatic castrate-resistant prostate cancer (mCRPC).
- Current data supports the use of small-molecule PSMA inhibitors, particularly Lu-PSMA, showing promising safety and effectiveness in heavily pre-treated patients.
- Ongoing clinical trials are exploring the theranostic approach's impact, suggesting it could play a crucial role not only in advanced stages of the disease but also in earlier stages of prostate cancer.
Article Abstract
Objectives: To review current data for the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) for patients with advanced prostate cancer. This review provides an update for multidisciplinary teams on the current and potential future applications of theranostics in prostate cancer.
Methods: Narrative review focussing on PSMA as a target for RLT, and data using RESULTS: RLT with PSMA is an exciting therapeutic alternative to the existing management options already in use for patients with metastatic castrate-resistant prostate cancer (mCRPC). To date, most evidence exists regarding small-molecule PSMA inhibitors bound to beta-emitting radioisotopes such as 177Lu (Lu-PSMA). Prospective phase II data supports the safety and efficacy of Lu-PSMA in men with heavily pre-treated progressive mCRPC, and several late-phase randomised trials of Lu-PSMA are underway, with many more in the pipeline. Early results are encouraging, indicating that the theranostic approach may play a vital role in management of advanced prostate cancer and perhaps even in much earlier disease states.
Conclusions: PSMA RLT is a promising new treatment option for men with mCPRC, and may also have utility in less advanced prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bju.15143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!